News | February 11, 2021
SMS Pharmaceuticals Q3FY21 consolidated PAT up to Rs. 21.39 Cr
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
Tavaborole Topical Solution, 5%, is an oxaborole antifungal.
The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
Subscribe To Our Newsletter & Stay Updated
